Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/13993003.00313-2022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis.
Am J Respir Crit Care Med
August 2025
Justus Liebig University, Internal Medicine, Giessen, Germany.
Background: Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. The PVRI GoDeep meta-registry collects real-world data of PH patients from international PH referral centers.
Methods: ILD-PH patients and relevant subgroups (IIP, IPF) were stratified by pulmonary vascular resistance (PVR).
Refining Risk Prediction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
J Am Soc Echocardiogr
July 2025
Division of Cardiology, Johns Hopkins University, Baltimore, Maryland. Electronic address:
Background: Pulmonary arterial hypertension (PAH) confers high morbidity and mortality, particularly in patients with systemic sclerosis (SSc), in which right ventricular (RV) adaptation to pulmonary artery (PA) afterload is a key determinant of outcome. Although several clinical risk scores aid in prognostication, their performance in SSc-associated PAH (SSc-PAH) is unclear. The aims of this study were to evaluate the association of established PAH risk scores with mortality in SSc-PAH and to assess whether echocardiographic RV-PA coupling metrics enhance risk discrimination.
View Article and Find Full Text PDFNT-proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point-of-Care and Remote Monitoring.
Respirology
July 2025
Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Background And Objectives: Brain natriuretic peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP) are important biomarkers in pulmonary arterial hypertension (PAH). However, results are rarely available at the time of clinical assessment. The reliability of NT-proBNP/BNP point-of-care tests (POCT) in PAH patients and the stability of NT-proBNP in posted blood samples, to simulate remote monitoring, was investigated.
View Article and Find Full Text PDFAssociation of Systemic Inflammatory Response Index with Disease Severity and Adverse Outcome in Chronic Thromboembolic Pulmonary Hypertension.
J Inflamm Res
June 2025
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People's Republic of China.
Background: Composite inflammatory markers, such as the systemic inflammatory response index (SIRI), are associated with the severity and progression of several cardiovascular diseases. However, the relationship between SIRI and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. We hypothesized that elevated SIRI levels would correlate with disease severity and independently predict adverse clinical outcomes in patients with CTEPH.
View Article and Find Full Text PDFLong-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model.
Adv Ther
August 2025
Department for Respiratory Medicine and Infectious Diseases, German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.
Introduction: Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with significant morbidity and mortality. The phase 3 STELLAR trial tested sotatercept plus background therapy (BGT) versus placebo plus BGT, where BGT included mono-, double-, or triple-PAH targeted therapy. Building on the trial's findings, a population health model was recently published assessing the long-term clinical impact of sotatercept.
View Article and Find Full Text PDF